Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats

Opioid withdrawal is one of the most significant barriers to recovery for individuals with substance use disorders. This study by Konstantinopolsky, Chernyakova, and Kolik investigated whether Selank, a peptide analog of the naturally occurring immunomodulatory peptide tuftsin, could attenuate the aversive symptoms of morphine withdrawal.

The researchers used a rat model of morphine withdrawal to evaluate Selank's effects on withdrawal severity. They assessed behavioral markers of distress, anxiety, and physical withdrawal symptoms to determine whether the peptide could provide meaningful relief during the withdrawal process.

The results demonstrated that Selank significantly attenuated the aversive signs of morphine withdrawal. The peptide reduced both the physical and emotional components of withdrawal, supporting its anxiolytic properties in a clinically relevant context.

These findings suggest Selank could serve as a valuable therapeutic aid in addiction recovery, helping patients manage the difficult withdrawal process without the sedation or dependency risks associated with conventional anxiolytic medications. This peptide-based approach to withdrawal support represents a promising direction in the development of safer addiction treatment tools.